Shanghai Ark Biopharmaceutical Co., Ltd. ((ArkBio) has received authorization from the U.S. Food and Drug Administration (FDA) to conduct a Phase 2 trial of ziresovir, an oral antiviral being developed for infants with severe respiratory syncytial virus infection, including patients requiring treatment in a pediatric intensive care unit.
The planned multicenter, randomized, double-blind and placebo-controlled study will evaluate whether ziresovir can improve clinically meaningful outcomes in severely ill hospitalized infants. Shanghai Ark Biopharmaceutical, commonly known as ArkBio, identified the duration of supplemental oxygen treatment and time to sustained recovery as important measures in the trial.
The company has not disclosed the planned enrollment, participating countries, dosing regimen, recruitment timeline or complete endpoint hierarchy. It also has not identified the study’s ClinicalTrials.gov registration number. Those details will be important for determining whether the trial is designed primarily to generate an early signal in critically ill patients or to establish a sufficiently robust foundation for a later registrational program.
The FDA action does not constitute approval of ziresovir as an RSV treatment. It means the agency has allowed the proposed clinical investigation to proceed under an investigational drug framework. Ziresovir remains an experimental therapy in the United States.
The decision nevertheless gives ArkBio a path into a patient population with limited treatment options and substantial medical need. Critically ill infants with RSV may require oxygen, noninvasive ventilation, mechanical ventilation or other intensive respiratory support. A treatment capable of shortening oxygen dependence or accelerating sustained recovery could have clinical and hospital-resource implications extending beyond an improvement in a symptom score.
Why is ziresovir entering Phase 2 after already producing positive Phase 3 results?
The apparent move from Phase 3 back to Phase 2 is not necessarily a backward step. ArkBio’s earlier pivotal study was conducted in China and enrolled a broader population of hospitalized infants and young children aged 1 to 24 months. The new FDA-cleared trial will concentrate on more severely ill infants, including those admitted to pediatric intensive care units.
That change in population matters. Critically ill patients can differ substantially from the broader hospitalized population in disease severity, organ function, supportive-care requirements, concurrent medications and the timing of antiviral treatment. A dose and endpoint strategy that worked in a conventional pediatric ward may need separate evaluation in infants receiving intensive respiratory support.
The previous trial also relied on the Wang bronchiolitis clinical score as its primary efficacy measure. That score evaluates respiratory rate, wheezing, chest retractions and general condition. It can detect changes in bronchiolitis symptoms, but questions have been raised about how completely it reflects outcomes that families, intensive-care physicians and regulators consider most consequential.
The FDA-cleared Phase 2 study appears designed to address that gap by examining oxygen duration and sustained recovery. Those endpoints could provide a more direct picture of whether antiviral activity translates into reduced respiratory support and earlier clinical stabilization.
US development also requires evidence that can be interpreted across a more geographically and clinically diverse population. The earlier Phase 3 trial was conducted entirely in China, limiting the ability to assume that its findings will transfer without additional confirmation to different health systems, patient demographics and standards of supportive care.
Rather than repeating the Chinese trial immediately as another large Phase 3 study, ArkBio can use the new trial to establish the appropriate design for a global registrational program in severe RSV. The outcome could influence patient-selection criteria, treatment timing, dose selection, endpoint definitions and statistical assumptions for the next stage.
What did the earlier ziresovir Phase 3 trial show in hospitalized infants?
ArkBio’s AIRFLO Phase 3 trial was a randomized, double-blind, placebo-controlled study conducted across 28 hospitals in China. It enrolled 311 infants and young children between 1 and 24 months of age, with separate safety, pharmacokinetic and efficacy components.
In the principal efficacy portion, 256 participants were randomized in a two-to-one ratio to receive ziresovir or placebo orally every 12 hours for five days. The intention-to-treat efficacy population included 244 patients, while the safety analysis covered 302 participants who received at least one dose across the trial’s two parts.
By the third day, the average Wang bronchiolitis clinical score had fallen by 3.4 points in the ziresovir group, compared with a 2.7-point reduction among placebo recipients. The adjusted difference was 0.8 points in favor of ziresovir and met the trial’s threshold for statistical significance.
The reduction in RSV viral load by the fifth day was also greater with ziresovir. Viral load fell by approximately 2.5 log10 copies per milliliter in the treatment group and 1.9 log10 copies per milliliter with placebo. The concurrent improvement in clinical symptoms and viral measurements supported the conclusion that the drug was producing direct antiviral activity rather than merely affecting how symptoms were recorded.
Benefits were observed in prespecified subgroups that included children with more severe baseline bronchiolitis and infants aged six months or younger. The younger subgroup is particularly relevant because the risk of severe RSV disease and hospitalization is concentrated in early infancy.
Treatment-related adverse events were reported in 16% of ziresovir recipients and 13% of placebo recipients. Diarrhea, elevated liver-enzyme levels and rash were among the more frequently reported events. The study did not identify a serious drug-related safety signal or any treatment-related deaths.
These findings were published in The New England Journal of Medicine in 2024. A subsequent analysis in The Lancet Child & Adolescent Health focused on infants aged six months or younger and included follow-up for recurrent wheezing and asthma-related outcomes.
The earlier results are encouraging, but their limitations help explain the new development strategy. The difference in the bronchiolitis score was statistically significant but comparatively modest, the score itself is not universally accepted as a definitive regulatory endpoint, and the study did not originally record time to discontinuation of oxygen as a central efficacy measure.
How is ziresovir designed to stop respiratory syncytial virus?
Ziresovir is an orally administered small molecule that inhibits the respiratory syncytial virus fusion protein. The candidate was originally discovered by Roche and was licensed to ArkBio, which obtained global development rights and advanced it through pediatric clinical studies.
The fusion protein allows RSV to enter respiratory cells by bringing the viral membrane and the host-cell membrane together. It also contributes to the formation of syncytia, in which infected cells merge with adjacent cells and facilitate the spread of infection through respiratory tissue.
Ziresovir binds to the fusion protein and stabilizes it in a form that cannot complete this membrane-fusion process. Blocking viral entry and cell-to-cell spread should reduce the number of newly infected cells, suppress viral replication and give the infant’s immune system an opportunity to control the existing infection.
This mechanism distinguishes ziresovir from preventive monoclonal antibodies. Products such as nirsevimab and clesrovimab also target the RSV fusion protein, but they are administered before infection to provide passive immunity during an RSV season. Ziresovir is being developed as a treatment after an infant has developed symptomatic disease.
An oral formulation could be advantageous because it avoids repeated injections or prolonged intravenous delivery. Pediatric administration still presents practical challenges, particularly in infants receiving intensive care. ArkBio will need to demonstrate reliable exposure in patients who may have feeding difficulties, gastrointestinal intolerance or other complications associated with severe illness.
Why would shorter oxygen use be a stronger endpoint for the new RSV trial?
Supplemental oxygen is a central component of supportive care for infants whose RSV infection causes hypoxemia or significant respiratory distress. The length of oxygen use can reflect both disease severity and the rate of recovery, although hospital protocols and discharge practices can influence the measurement.
A treatment that reliably reduces oxygen duration could potentially shorten hospital stays, ease pressure on pediatric intensive-care beds and lower the risk associated with prolonged respiratory support. It could also give regulators a more readily interpretable measure than a composite symptom score.
Sustained recovery is similarly relevant because an infant may show temporary improvement before deteriorating again. A well-defined sustained-recovery endpoint can require the patient to remain clinically stable without a return to oxygen, intensive respiratory support or another specified level of care.
The precise definitions will determine the trial’s quality. ArkBio will need to establish when the endpoint clock starts, how transfers between intensive-care and general wards are handled, whether different oxygen-delivery methods are counted equally and how deaths or treatment escalation are incorporated into the analysis.
Timing of antiviral administration will be another critical variable. RSV viral replication is generally most active early in the disease course. Patients may enter intensive care only after inflammation and airway damage have become major drivers of illness, potentially reducing the benefit achievable through viral suppression alone.
The trial should therefore clarify the interval between symptom onset, laboratory confirmation, hospitalization, intensive-care admission and the first ziresovir dose. If treatment begins too late, an effective antiviral mechanism may produce a strong viral-load effect without generating an equally large clinical benefit.
What resistance signal emerged from the previous ziresovir study?
Resistance-associated mutations were detected in 15 ziresovir-treated participants in the AIRFLO trial, representing approximately 9% of recipients in the efficacy study. The mutations occurred among patients receiving the higher dose and were not found in the placebo group.
Antiviral resistance is an important issue for drugs that target a specific viral protein. Mutations in or near the binding site can reduce the drug’s ability to inhibit fusion, allowing less-susceptible viral variants to continue replicating.
The earlier trial did not identify a corresponding serious safety problem, but the emergence of resistance-associated variants requires continued investigation. Pediatric patients can carry high viral loads, and severely ill infants may remain infected for longer periods, especially if they have underlying immune or cardiopulmonary conditions.
The new Phase 2 trial should include viral sequencing before treatment and at defined points after dosing, particularly in patients who experience delayed viral clearance, clinical deterioration or rebound. Regulators will want to understand whether resistant variants are transmitted, whether they remain clinically fit and whether they reduce susceptibility to preventive antibodies that also target the fusion protein.
This issue does not erase the efficacy signal, but it prevents the development story from being reduced to symptom improvement alone. A successful RSV antiviral must combine clinical benefit with an acceptable resistance profile when used across potentially large seasonal populations.
How does ziresovir fit into an RSV market increasingly focused on prevention?
The RSV landscape has changed significantly through the introduction of vaccines for older adults and pregnant individuals, along with long-acting monoclonal antibodies for infants. In the United States, nirsevimab and clesrovimab can provide passive protection against lower respiratory tract disease during an infant’s first RSV season, with nirsevimab also available for certain vulnerable children entering a second season.
Those preventive products can reduce infection-related medical visits and hospitalizations, but they do not remove the need for treatment. Coverage varies between countries and health systems, some infants remain unprotected, and preventive antibodies cannot guarantee that every exposed child will avoid severe disease.
Supportive care consequently remains the foundation of treatment for most hospitalized infants. Oxygen, hydration and respiratory support are used according to clinical need. Aerosolized ribavirin has an RSV treatment indication in the United States, but its limited evidence, administration complexity, safety considerations and cost have prevented routine use in most otherwise healthy children.
Ziresovir’s commercial opportunity therefore depends on becoming a practical, modern direct-acting treatment rather than competing directly with preventive immunization. Its most defensible initial role may be in hospitalized infants with laboratory-confirmed RSV who remain at risk of respiratory deterioration despite supportive care.
A positive intensive-care trial would strengthen that positioning. It would also help ArkBio show that ziresovir adds value in an era when preventive products may reduce the total number of hospitalized cases but leave a smaller concentration of particularly vulnerable or severe patients.
What does the FDA clearance mean for ArkBio’s global strategy?
ArkBio was founded in 2014 and licensed global rights to ziresovir from Roche during its early development. The Shanghai-based biotechnology company has since built a respiratory and pediatric pipeline that includes an antifibrotic candidate for idiopathic pulmonary fibrosis, an RSV-prevention antibody and an influenza antiviral-Fc conjugate.
The company became commercial-stage in China through Aizhida, a therapy for attention-deficit hyperactivity disorder that received Chinese marketing authorization in January 2026. Ziresovir remains its most advanced internally developed infectious-disease opportunity.
China’s National Medical Products Administration accepted a ziresovir marketing application and granted Priority Review in 2022, while the candidate has also received Chinese Breakthrough Therapy designation. ArkBio has not announced a Chinese marketing approval for ziresovir, however, and the drug remains investigational.
The World Health Organization included ziresovir in its 2025 pediatric RSV drug-optimization work, highlighting the need for child-appropriate treatment options. That recognition supports the program’s public-health relevance but does not substitute for regulatory approval or country-specific clinical evidence.
The FDA-cleared study gives ArkBio an opportunity to turn a China-centered development program into a broader global asset. It may also improve the company’s position in potential licensing or commercialization discussions, since a partner would gain more confidence from an FDA-aligned clinical pathway than from relying exclusively on Chinese efficacy data.
What results would make the new ziresovir trial genuinely persuasive?
A favorable trial would need to show more than a reduction in viral load. The most compelling result would be a clinically meaningful and statistically credible reduction in oxygen duration or time to sustained recovery, supported by consistent improvements in respiratory-support intensity, intensive-care stay and hospital discharge.
The safety analysis will need to be particularly detailed because the participants are infants with severe disease. Liver-enzyme changes, gastrointestinal events, cardiac findings, dosing interruptions and deaths should be evaluated against the background complication rate expected in an intensive-care RSV population.
Resistance monitoring should be integrated rather than treated as a secondary laboratory exercise. A therapy intended for broad pediatric use will need a clear account of when resistant substitutions emerge, how long they persist and whether they affect treatment response.
ArkBio must also disclose how many patients receive invasive ventilation, noninvasive ventilation, high-flow oxygen or conventional oxygen at enrollment. A result driven primarily by infants at the less severe end of the intensive-care spectrum would have different implications from one reproduced across multiple levels of respiratory support.
The FDA clearance is therefore an entry point, not the decisive event. The trial’s design and eventual clinical outcomes will determine whether ziresovir can progress from a promising China-based Phase 3 program into a globally relevant treatment for infants who already have severe RSV disease.
